HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A Douglas Laird Selected Research

XL765

9/2015Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
5/2014Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
5/2014Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.
3/2014Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


A Douglas Laird Research Topics

Disease

21Neoplasms (Cancer)
01/2022 - 05/2002
3Breast Neoplasms (Breast Cancer)
01/2022 - 10/2002
3Prostatic Neoplasms (Prostate Cancer)
01/2021 - 10/2014
3Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2021 - 06/2017
3Neoplasm Metastasis (Metastasis)
12/2011 - 10/2002
2Residual Neoplasm
01/2022 - 01/2020
2Disease Progression
01/2021 - 10/2014
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2019 - 01/2018
2Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/2019 - 01/2018
2Glioma (Gliomas)
09/2015 - 12/2011
1Leukemia
01/2022
1Adenocarcinoma
01/2021
1Pneumonia (Pneumonitis)
01/2019
1Fatigue
01/2019
1Respiratory Insufficiency (Respiratory Failure)
11/2016
1Hypoxia (Hypoxemia)
01/2016
1Circulating Neoplastic Cells
10/2014
1Pain (Aches)
10/2014
1Lung Neoplasms (Lung Cancer)
03/2014
1Nausea
01/2014
1Diarrhea
01/2014
1Carcinogenesis
12/2011
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/2007
1Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic)
07/2004
1Hematologic Neoplasms (Hematological Malignancy)
07/2004
1Inflammation (Inflammations)
11/2003
1Diabetic Retinopathy (Retinopathy, Diabetic)
09/2003
1Macular Degeneration (Age-Related Maculopathy)
09/2003

Drug/Important Bio-Agent (IBA)

9Phosphotransferases (Kinase)IBA
01/2022 - 10/2002
5tyrosine receptor (receptor, tyrosine)IBA
10/2014 - 10/2002
4cabozantinibIBA
11/2016 - 12/2011
4XL765IBA
09/2015 - 03/2014
4Sunitinib (Sutent)FDA Link
06/2015 - 01/2003
4Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
06/2015 - 05/2002
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
12/2011 - 05/2003
3Inotuzumab OzogamicinIBA
01/2021 - 06/2017
3Biomarkers (Surrogate Marker)IBA
01/2016 - 03/2014
3Proteins (Proteins, Gene)FDA Link
04/2012 - 10/2002
3Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
12/2011 - 05/2006
2Poly(ADP-ribose) Polymerase InhibitorsIBA
01/2022 - 01/2021
2talazoparibIBA
01/2022 - 01/2021
2Cytarabine (Cytosar-U)FDA LinkGeneric
01/2019 - 01/2018
2glasdegibIBA
01/2019 - 01/2018
2Pharmaceutical PreparationsIBA
11/2016 - 01/2014
2Tyrosine Kinase InhibitorsIBA
11/2016 - 01/2003
2Tyrosine (L-Tyrosine)FDA Link
11/2016 - 01/2003
2Phosphatidylinositols (Phosphatidylinositol)IBA
09/2015 - 05/2014
2TOR Serine-Threonine KinasesIBA
09/2015 - 03/2014
2XL147IBA
04/2015 - 01/2014
2ErbB Receptors (EGF Receptor)IBA
03/2014 - 06/2007
2LigandsIBA
12/2011 - 07/2006
2Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA
07/2006 - 07/2004
2Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
07/2004 - 10/2002
2orantinib (SU6668)IBA
10/2002 - 05/2002
1RNA (Ribonucleic Acid)IBA
01/2022
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
01/2021
1enzalutamideIBA
01/2021
1abirateroneIBA
01/2021
1taxaneIBA
01/2021
1Indicators and Reagents (Reagents)IBA
01/2020
1DecitabineFDA Link
01/2018
1Daunorubicin (Cerubidine)FDA LinkGeneric
01/2018
1Alkaline PhosphataseIBA
01/2016
1Interleukin-8 (Interleukin 8)IBA
01/2016
1ClusterinIBA
01/2016
1Temozolomide (Temodar)FDA LinkGeneric
09/2015
1Analgesics (Analgesic Drugs)IBA
10/2014
1Narcotics (Narcotic Analgesics)IBA
10/2014
1Mechanistic Target of Rapamycin Complex 1IBA
05/2014
1Mechanistic Target of Rapamycin Complex 2IBA
05/2014
1Class I Phosphatidylinositol 3-KinasesIBA
03/2014
1Mitogen-Activated Protein KinasesIBA
03/2014
1Erlotinib Hydrochloride (CP 358,774)FDA Link
03/2014
1Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
12/2011
1XL647IBA
06/2007
1Docetaxel (Taxotere)FDA Link
07/2006
1Proto-Oncogene Proteins c-kit (Proto-Oncogene Protein c-kit)IBA
07/2006
1fms-Like Tyrosine Kinase 3IBA
07/2006
15- ((5- fluoro- 2- oxo- 1,2- dihydro- 3H- indol- 3- ylidene)methyl)- N- (2- hydroxy- 3- morpholin- 4- ylpropyl)- 2,4- dimethyl- 1H- pyrrole- 3- carboxamideIBA
07/2006
1Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
07/2006
1Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
07/2006
1Imatinib Mesylate (Gleevec)FDA Link
05/2006
1Platelet-Derived Growth FactorIBA
05/2006
13- (5- methyl- 2- (2- oxo- 1,2- dihydroindol- 3- ylidenemethyl)- 1H- pyrrol- 3- yl)propionic acidIBA
05/2006
1SU 11657IBA
07/2004
1STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
05/2003
1Focal Adhesion Protein-Tyrosine KinasesIBA
05/2003
1AgarIBA
05/2003
1src-Family KinasesIBA
05/2003
1EpitopesIBA
05/2003
1Immunoglobulin G (IgG)IBA
10/2002
1Angiogenesis InhibitorsIBA
10/2002

Therapy/Procedure

7Therapeutics
06/2015 - 10/2002
5Drug Therapy (Chemotherapy)
01/2022 - 10/2014
3Castration
01/2021 - 10/2014
1Remission Induction
01/2022
1Induction Chemotherapy
01/2018
1Radiotherapy
09/2015
1Oral Administration
07/2004